<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Paroxetine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00715</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &#945;- or &#946;-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (<span class="caps">FDA</span>); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (<span class="caps">MDD</span>), panic disorder with or without agoraphobia, obsessive-compulsive disorder (<span class="caps">OCD</span>), social anxiety disorder (social phobia), generalized anxiety disorder (<span class="caps">GAD</span>), post-traumatic stress disorder (<span class="caps">PTSD</span>) and premenstrual dysphoric disorder (<span class="caps">PMDD</span>). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00715/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00715/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00715.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00715.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00715.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00715.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00715.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00715">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Paroxetine Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000132/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000132/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: GELRVIPPMNMYGS-RVXRQPKJSA-N</li>
              <li>Monoisotopic Mass: 365.119399455</li>
              <li>Average Mass: 365.826</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000132">DBSALT000132</a></td>
      </tr>
      <tr>
        <td>
          <strong>Paroxetine Mesylate </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000133/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000133/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: SHIJTGJXUHTGGZ-RVXRQPKJSA-N</li>
              <li>Monoisotopic Mass: 425.1308364</li>
              <li>Average Mass: 425.471</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000133">DBSALT000133</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aropax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Brisdelle </td><td>Noven Pharmaceuticals</td></tr><tr><td>Paxil</td><td>GlaxoSmithKline</td></tr><tr><td>Paxil CR</td><td>GlaxoSmithKline</td></tr><tr><td>PAXILCR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pexeva</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sereupin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Seroxat</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Seroxat CR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/serotonin-uptake-inhibitors">Serotonin Uptake Inhibitors</a></li>
<li><a href="/mesh/antidepressive-agents">Antidepressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>61869-08-7</td></tr><tr><th>Weight</th><td>Average: 329.3654<br>Monoisotopic: 329.142721716</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>20</sub>FNO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>AHOUBRCZNHFOSL-YOEHRIQHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Piperidines</td></tr><tr><th>Subclass</th><td>Phenylpiperidines</td></tr><tr><th>Direct parent</th><td>Phenylpiperidines</td></tr><tr><th>Alternative parents</th><td>Benzodioxoles; Phenol Ethers; Alkyl Aryl Ethers; Fluorobenzenes; Aryl Fluorides; Dialkylamines; Acetals; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>benzodioxole; phenol ether; fluorobenzene; alkyl aryl ether; benzene; aryl halide; aryl fluoride; secondary amine; polyamine; secondary aliphatic amine; ether; acetal; organofluoride; organohalogen; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause. </td></tr><tr><th>Pharmacodynamics</th><td>Paroxetine, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type, has no active metabolites and has the highest specificity for serotonin receptors of all the SSRIs. It is used to treat depression resistant to other antidepressants, depression complicated by anxiety, panic disorder, social and general anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder, premature ejaculation, and hot flashes of menopause in women with breast cancer. In human platelets, paroxetine blocks the uptake of serotonin. It has weak effects on norepinephrine and dopamine neuronal reuptake.  In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors.  </td></tr><tr><th>Mechanism of action</th><td>Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown. </td></tr><tr><th>Absorption</th><td>Paroxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable. </td></tr><tr><th>Volume of distribution</th><td><p>3.1-28 L/kg observed in animal studies. Paroxetine distributes throughout the body, including the central nervous system, with only 1% remaining in the plasma.</p></td></tr><tr><th>Protein binding</th><td>~ 95% bound to plasma proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Paroxetine is extensively metabolized after oral administration, likely in the liver. The main metabolites are polar and conjugated products of oxidation and methylation, which are readily eliminated by the body. The predominant metabolites are glucuronic acid and sulfate conjugates. Paroxetine metabolites do not possess significant pharmacologic activity (less than 2% that of parent compound). Paroxetine is metabolized by cytochrome P450 (CYP) 2D6. Enzyme saturation appears to account for the nonlinear pharmacokinetics observed with increasing dose and duration of therapy. </p></td></tr><tr><th>Route of elimination</th><td>Approximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites. Approximately 36% of the dose was excreted in the feces (via bile), mostly as metabolites and less than 1% as parent compound. </td></tr><tr><th>Half life</th><td>21-24 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=500mg/kg (orally in mice). Symptoms of overdose include: coma, dizziness, drowsiness, facial flushing, nausea, sweating, tremor, vomiting. Side effects include: nervous system effects such as asthenia, somnolence, dizziness, insomnia, tremor, and nervousness; GI effects such as nausea, decreased appetite, constipation, diarrhea, and dry mouth; impotence, ejaculatory dysfunction (principally ejaculatory delay), and other male genital disorders; female genital disorders (principally anorgasmia or difficulty reaching climax/orgasm); and sweating. Discontinuation syndrome may occur with abrupt withdrawal. Symptoms of discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory changes, and hyperactivity. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Multidrug resistance protein 1<br>Gene symbol: ABCB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08183" target="_blank">P08183 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2032583" target="_blank">rs2032583 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response to antidepressant medication</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17913323" target="_blank" title="Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. [18215618 ]
    Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T: ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):398-404. Epub 2007 Sep 15.">17913323 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>5-hydroxytryptamine receptor 1A<br>Gene symbol: HTR1A<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08908" target="_blank">P08908 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs6295" target="_blank">rs6295 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>C Allele potentially associated with discontinuation syndrome in patients treated for anxiety or depression.</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/20075642" target="_blank" title='# Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R, Koyama S, Mine K: Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010 Feb;30(1):11-7. doi: 10.1097/JCP.0b013e3181c8ae80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20075642'>20075642 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9869</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5195</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6555</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8564</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6771</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5222</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9265</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6004</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8948</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8298</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8649</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6722
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9046
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.995
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.8239 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5554
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5879
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Glaxosmithkline</li>
<li>Apotex inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Actavis elizabeth llc</li>
<li>Alphapharm pty ltd</li>
<li>Aurobindo pharma ltd</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Roxane laboratories inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Noven therapeutics llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aidarex.com">Aidarex Pharmacuticals LLC</a></li>
<li><a href="http://www.alphapharm.com.au">Alphapharm Party Ltd.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.excella-pharma-source.de">Excella GmbH</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>International Laboratories Inc.</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.norwichpharma.com">Norwich Pharmaceuticals Inc.</a></li>
<li><a href="http://www.noven.com">Noven Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Penn Labs</li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li>Rubin Neudecker Medical Research Laboratories Ltd.</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.synthon.com">Synthon Pharmaceuticals Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>7.5 mg</td></tr><tr><td>Suspension</td><td>Oral</td><td>10 mg/5 mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>10 mg, 20 mg, 30 mg, 40 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>12.5 mg, 25 mg, 37.5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The SSRI, paroxetine, increases the effect of the anticoagulant, acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00182">Amphetamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The SSRI, paroxetine, increases the effect of the anticoagulant, anisindione.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Paroxetine is a substrate of CYP2D6 and concomitant therapy with asenapine (CYP2D6 inhibitor) increases concentrations of paroxetine 2-fold. May require dosing adjustments. </td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>The CYP2D6 inhibitor, paroxetine, may increase the effect and toxicity of atomoxetine.</td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, carvedilol.</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The SSRI, paroxetine, increases the effect of anticoagulant, dicumarol.
</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01551">Dihydrocodeine</a></td><td>Opioid analgesics may enhance the 5HT effects of SSRIs to cause serotonin syndrome. It is recommended to monitor therapy.</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Paroxetine increases the effect and toxicity of galantamine</td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB04946">Iloperidone</a></td><td>Paroxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% </td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>The SSRI increases the effect of the beta-blocker</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00497">Oxycodone</a></td><td>Increased risk of serotonin syndrome</td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias.</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Paroxetine may increase the effect and toxicity of propafenone.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, propranolol.</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00734">Risperidone</a></td><td>The SSRI, paroxetine, increases the effect and toxicity of risperidone.</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort increases the effect and toxicity of the SSRI, paroxetine.</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Paroxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Paroxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Paroxetine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Paroxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Paroxetine if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>Paroxetine is a strong CYP2D6 inhibitor thus increasing half life of dihydrotetrabenazine moieties. Dose of tetrabenazine should be reduced </td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir increases the concentration of Paroxetine. The Paroxetine dose may require an adjustment.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Paroxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizures. Paroxetine may decrease the effect of Tramadol by decreasing active metabolite production.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Paroxetine. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The SSRI, Paroxetine, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Paroxetine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Paroxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The SSRI, paroxetine, increases the effect of the anticoagulant, warfarin.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and paroxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals. Avoid alcohol.</li></ul></td></tr></tbody></table>